[go: up one dir, main page]

ATE464064T1 - ACTIVATION OF ANTIGEN-SPECIFIC T CELLS WITH VIRUS/ANTIGEN-TREATED DENDRITIC CELLS - Google Patents

ACTIVATION OF ANTIGEN-SPECIFIC T CELLS WITH VIRUS/ANTIGEN-TREATED DENDRITIC CELLS

Info

Publication number
ATE464064T1
ATE464064T1 AT00969488T AT00969488T ATE464064T1 AT E464064 T1 ATE464064 T1 AT E464064T1 AT 00969488 T AT00969488 T AT 00969488T AT 00969488 T AT00969488 T AT 00969488T AT E464064 T1 ATE464064 T1 AT E464064T1
Authority
AT
Austria
Prior art keywords
antigen
cells
activation
specific
virus
Prior art date
Application number
AT00969488T
Other languages
German (de)
Inventor
Thorsten Dr Ahlert
Original Assignee
Thorsten Dr Ahlert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thorsten Dr Ahlert filed Critical Thorsten Dr Ahlert
Application granted granted Critical
Publication of ATE464064T1 publication Critical patent/ATE464064T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a vaccine containing virus/antigen-treated dendritic cells (DC) which stimulate an immune response in a patient obtainable by the activation of antigen-specific T cells (TC) in vivo, to a composition containing activated TC which are activated by the vaccine in vitro, to a pharmaceutical composition containing the vaccine and/or the composition as well as to methods for their production.
AT00969488T 1999-10-13 2000-10-11 ACTIVATION OF ANTIGEN-SPECIFIC T CELLS WITH VIRUS/ANTIGEN-TREATED DENDRITIC CELLS ATE464064T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99119980A EP1092439A1 (en) 1999-10-13 1999-10-13 Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
PCT/EP2000/010019 WO2001026680A2 (en) 1999-10-13 2000-10-11 Activation of antigen-specific t cells by virus/antigen-treated dendritic cells

Publications (1)

Publication Number Publication Date
ATE464064T1 true ATE464064T1 (en) 2010-04-15

Family

ID=8239146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00969488T ATE464064T1 (en) 1999-10-13 2000-10-11 ACTIVATION OF ANTIGEN-SPECIFIC T CELLS WITH VIRUS/ANTIGEN-TREATED DENDRITIC CELLS

Country Status (10)

Country Link
US (1) US20090060946A1 (en)
EP (2) EP1092439A1 (en)
JP (1) JP2003511419A (en)
AT (1) ATE464064T1 (en)
AU (1) AU782196B2 (en)
CA (1) CA2387063A1 (en)
DE (1) DE60044198D1 (en)
DK (1) DK1221969T3 (en)
ES (1) ES2343673T3 (en)
WO (1) WO2001026680A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1092439A1 (en) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
WO2019046818A1 (en) * 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806565A1 (en) * 1988-03-01 1989-09-14 Deutsches Krebsforsch VIRUS-MODIFIED TUMOR VACCINES FOR THE IMMUNOTHERAPY OF TUMOR METAL KEYS
KR960701208A (en) * 1993-03-16 1996-02-24 엔 엔 데이비스 STIMULATION OF IMMUNE RESPONSE BY VIRAL PROTEIN
DE4407538C1 (en) * 1994-03-07 1995-02-23 Deutsches Krebsforsch Binding reagent for cell surface protein and effector cell
EP1092439A1 (en) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells

Also Published As

Publication number Publication date
WO2001026680A2 (en) 2001-04-19
AU782196B2 (en) 2005-07-07
JP2003511419A (en) 2003-03-25
DE60044198D1 (en) 2010-05-27
EP1221969B1 (en) 2010-04-14
ES2343673T3 (en) 2010-08-06
US20090060946A1 (en) 2009-03-05
AU7918400A (en) 2001-04-23
EP1221969A2 (en) 2002-07-17
EP1092439A1 (en) 2001-04-18
DK1221969T3 (en) 2010-08-02
WO2001026680A3 (en) 2001-11-08
CA2387063A1 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
ATE276758T1 (en) ADJUVANT COMPOSITION CONTAINING SAPONIN AND AN IMMUNO-STIMULATIVE OLIGONUCLEOTIDE
BRPI0414381A (en) adjuvant composition, immunogenic composition (s), vaccine composition, process for the manufacture of an immunogenic composition, pharmaceutical composition (s), kit, methods for treating a patient suffering from, or susceptible to, a tumor, to enhance a mammalian immune response to an antigen and to elicit a mammalian immune response against a disease state, uses an imidazoquinoline or derivative thereof and gm-csf and components
WO2015149944A3 (en) Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
DE60138641D1 (en) PREPARATION OF MICRO BEADS
WO2009044273A3 (en) Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
BR0314373A (en) Stable immunogenic product for the induction of antibodies to one or more antigenic proteins in a subject, pharmaceutical, immunogenic and vaccine compositions and process of preparation of an immunogenic product
WO2002064757A3 (en) Influenza viruses with enhanced transcriptional and replicational capacities
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
ATE481088T1 (en) EMBOLIZATION USING POLY-4-HYDROXYBUTYRATE PARTICLES
ATE418344T1 (en) FUSION CELLS AND CYTOKINE COMPOSITIONS FOR TREATING DISEASES
MX2010006984A (en) Vaccines for malaria.
TR200001948T2 (en) Compositions derived from mycobacterium vacca and methods for their use.
BR0015597A (en) Use of antibodies as vaccines
ATE503491T1 (en) IMPROVED ANTHRAX VACCINES AND DELIVERY METHODS
ATE464064T1 (en) ACTIVATION OF ANTIGEN-SPECIFIC T CELLS WITH VIRUS/ANTIGEN-TREATED DENDRITIC CELLS
WO2000073432A3 (en) Activation of dendritic cells to enhance immunity
EE200200157A (en) The vaccine
ATE285250T1 (en) USE OF POLYMERS OF HYALURONIC ACID FOR MUCOSAL RELEASE OF VACCINES AND ADJUVANTS
MY127452A (en) Vaccines.
TW200509964A (en) VP1 of foot-and-mouth disease virus
AU2003214645A1 (en) Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours
ATE356632T1 (en) MELANOMA VACCINE AND ITS PRODUCTION AND USE
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
DE60010230D1 (en) PHARMACEUTICAL COMPOSITION OF HYDROPHOBICALLY MODIFIED HEDGEHOG PROTEINS AND THEIR USE
DE60336596D1 (en) LOCAL SPECIFIC ADMINISTRATION OF ACTIVE SUBSTANCES IN THE DARM

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1221969

Country of ref document: EP